Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Connect Biopharma will webcast a September 15, 2026 fireside chat for investors, with replay access available for about three months.
Rhea-AI Summary
Connect Biopharma (CNTB) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11:30 a.m. ET.
The live webcast will be accessible through the Investors section of the company’s website, and an archived replay will remain available online for approximately 90 days after the conference.
Positive
- None.
Negative
- None.
Market Reaction – CNTB
Following this news, CNTB has gained 3.63%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 113 alerts so far, indicating very high trading interest and price volatility. The stock is currently trading at $2.00. Trading volume is exceptionally heavy at 7.8x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Second-quarter earnings | Positive | +8.8% | Enrollment completion and September topline-data timing supported a positive clinical-development update. |
| Jun 17 | Phase 2 enrollment | Positive | +4.5% | Asthma enrollment completion preceded expected topline data and FDA discussions regarding a Phase 3 program. |
| May 12 | Investor conference notice | Neutral | -8.6% | Fireside chat announcement lacked operating or clinical results, preceding a negative reaction. |
| May 12 | First-quarter earnings | Positive | +14.5% | Private placement, cash runway guidance, and ongoing Phase 2 development accompanied quarterly results. |
| Apr 23 | Interim clinical analysis | Positive | -3.1% | Interim review found no safety concerns and enrollment continued, but shares declined. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Three of the five prior events had positive 24-hour reactions, while the May 12 conference notice and April 23 clinical update diverged negatively.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 11:30 a.m. ET.
The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately
For more information visit www.connectbiopharma.com.
Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
